Since the end of July, Amgen Inc.’s share price has dropped 14 percent – a slump that coincides with new competition the Thousand Oaks company is facing for one of its established drugs, as well as a period of increased turbulence in the overall stock market....

Subscribe to get the full story.


Are you a subscriber? Sign In